AMH Equity Ltd Sells 20,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

AMH Equity Ltd reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 20.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 80,000 shares of the biotechnology company’s stock after selling 20,000 shares during the quarter. AMH Equity Ltd’s holdings in BioCryst Pharmaceuticals were worth $602,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of BCRX. Venturi Wealth Management LLC purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at about $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $48,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. KBC Group NV increased its position in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares during the period. Finally, Quantinno Capital Management LP bought a new position in BioCryst Pharmaceuticals in the third quarter worth about $82,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BCRX shares. JMP Securities reiterated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC lifted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Barclays upped their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Trading Up 1.0 %

NASDAQ BCRX opened at $8.36 on Thursday. The stock’s fifty day moving average price is $8.07 and its 200-day moving average price is $7.85. The stock has a market cap of $1.73 billion, a P/E ratio of -13.70 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. The business’s revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.28 earnings per share. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.